[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848 230 7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of \u00df-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 127, "maxAge": 86400, "priceHint": 4, "previousClose": 3.61, "open": 3.5022, "dayLow": 3.5022, "dayHigh": 3.65, "regularMarketPreviousClose": 3.61, "regularMarketOpen": 3.5022, "regularMarketDayLow": 3.5022, "regularMarketDayHigh": 3.65, "forwardPE": -1.5145228, "volume": 2395, "regularMarketVolume": 2395, "averageVolume": 16904, "averageVolume10days": 14590, "averageDailyVolume10Day": 14590, "marketCap": 134686096, "fiftyTwoWeekLow": 3.21, "fiftyTwoWeekHigh": 19.3, "priceToSalesTrailing12Months": 26.93722, "fiftyDayAverage": 9.95612, "twoHundredDayAverage": 9.460885, "currency": "USD", "enterpriseValue": 336882944, "floatShares": 52398012, "sharesOutstanding": 36900300, "sharesShort": 12033, "sharesShortPriorMonth": 5685, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.00029999999, "heldPercentInsiders": 0.06957, "heldPercentInstitutions": 0.00193, "shortRatio": 1.66, "shortPercentOfFloat": 0.00029999999, "impliedSharesOutstanding": 36900300, "bookValue": 2.152, "priceToBook": 1.6960968, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -104871000, "trailingEps": -7.26, "forwardEps": -2.41, "enterpriseToRevenue": 67.377, "enterpriseToEbitda": -5.08, "52WeekChange": -0.75666666, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ANL", "underlyingSymbol": "ANL", "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "firstTradeDateEpochUtc": 1695994200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "291e650f-3a34-3dde-b7b9-4183619f74d0", "messageBoardId": "finmb_1830112145", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.65, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 98723000, "totalCashPerShare": 0.892, "ebitda": -66313000, "totalDebt": 31548000, "quickRatio": 1.962, "currentRatio": 2.011, "totalRevenue": 5000000, "debtToEquity": 39.731, "revenuePerShare": 0.346, "returnOnAssets": -0.4164, "freeCashflow": -34558752, "operatingCashflow": -56652000, "grossMargins": 1.0, "operatingMargins": -7.0852003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]